Alaunos Therapeutics, Inc. short interest in 2025
In 2025, Alaunos Therapeutics, Inc.'s disclosed short interest ran from 3.39% of shares outstanding on 15 Jan 2025 to 1.70% on 31 Dec 2025, a change of -1.69 percentage points. The year's high was 5.37% on 30 Jun 2025 and its low 0.55% on 15 Aug 2025, averaging 3.07% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.10 days on 28 Feb 2025. Full history: Alaunos Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 3.39% (15 Jan 2025)
- End of year
- 1.70% (31 Dec 2025)
- Change
- -1.69 pp
- High
- 5.37% (30 Jun 2025)
- Low
- 0.55% (15 Aug 2025)
- Average
- 3.07%
- Highest days to cover
- 8.10 (28 Feb 2025)
- SEC filings marked
- 4
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 3.39% | 4.29 | |
| 31 Jan 2025 | 4.11% | 2.57 | |
| 14 Feb 2025 | 3.39% | 4.87 | |
| 28 Feb 2025 | 3.69% | 8.10 | |
| 14 Mar 2025 | 3.23% | 4.04 | |
| 31 Mar 2025 | 2.87% | 4.74 | 10-K filed |
| 15 Apr 2025 | 5.04% | 1.00 | |
| 30 Apr 2025 | 2.91% | 1.88 | |
| 15 May 2025 | 3.48% | 2.29 | 10-Q filed |
| 30 May 2025 | 2.68% | 4.89 | |
| 13 Jun 2025 | 2.40% | 2.00 | |
| 30 Jun 2025 | 5.37% | 1.13 | |
| 15 Jul 2025 | 3.54% | 1.00 | |
| 31 Jul 2025 | 1.72% | 1.00 | |
| 15 Aug 2025 | 0.55% | 1.00 | 10-Q filed |
| 14 Nov 2025 | 3.22% | 1.92 | 10-Q filed |
| 28 Nov 2025 | 3.14% | 1.10 | |
| 15 Dec 2025 | 1.98% | 1.00 | |
| 31 Dec 2025 | 1.70% | 1.00 |
See also: Alaunos Therapeutics, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.